


12-13-04

11/16/04

<b>INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(D)</b>    Address to: Mail Stop AF Commissioner for Patents P.O. Box 1450	Attorney Docket	UCAL-161DIV
	First Named Inventor	FINKBEINER, STEVEN
	Application Number	09/922,483
	Filing Date	August 2, 2001
	Group Art Unit	1648
	Examiner Name	WINKLER, ULRIKE
	Title: "ANTIBODIES SPECIFIC FOR PROTEINS HAVING POLYGLUTAMINE EXPANSIONS"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed after a Final Action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

A Form SB08 (substitute for form 1449) listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

**Statement(s) under 37 CFR § 1.97(e):**

- ☒ (1) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.


This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

In accordance with the requirements of 37 C.F.R. §1.97(d) accompanying this paper is a certification as specified in 37 C.F.R. §1.97(e). Applicant(s) hereby petition for the consideration of this Information Disclosure Statement.


The \$180.00 fee set forth in 37 C.F.R. §1.17(p) to cover the petition accompanies this disclosure statement. The Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. UCAL-161DIV may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Dec. 10, 2004

By:   
Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650)327-3231



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	09/922,483		
		Filing Date	August 2, 2001		
		First Named Inventor	FINKBEINER, STEVEN		
		Group Art Unit	1648		
Sheet	1	of	1	Examiner Name	WINKLER, ULRIKE
				Attorney Docket Number	UCAL-161DIV

<b>OTHER ART—NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Dorsman et al. "Analysis of the subcellular localization of huntintin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of Huntington in huntington's disease autopsy brain" Philosophical Transactions. Royal Society of London. Biological Sciences, Royal Society, London GB, Vol. 354. No. 1386, June 1999 pgs. 1061-1067	
		Wilkinson et al. "Localization of rabbit Huntington using a new panel of monoclonal antibodies" Molecular Brain Research, Elsevier Science BV, Amsterdam, NL, Vol. 69, No. 1, 1999, pgs. 10-20	
		Trottier et al. "Polyglutamine expansion as a pathological epitope in huntington's disease and four dominant cerebellar ataxias" Nature, Macmillan Journals Ltd. London, GB, Vol. 378, No. 6555, November 23, 1995	
		Perutz "Glutamine repeats and inherited neurodegenerative diseases: molecular aspects" Current Opinion in Structural Biology, Current Biology Ltd., London, GB, Vol. 6, No. 6, 1996, pgs. 848-858	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.